Effect of Dipyridamole Injected for Myocardial Perfusion Imaging on Blood Glucose Concentration; A Preliminary Study
Introduction: Dipyridamole inhibits adenosine reuptake and increases cyclic Adenosine Monophosphate (cAMP) levels in platelets, erythrocytes and endothelial cells, all of which influence blood glucose. Acute hyperglycaemia reduces endothelium-dependent vasodilation and suppresses coronary micro...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
JCDR Research and Publications Private Limited
2016-08-01
|
Series: | Journal of Clinical and Diagnostic Research |
Subjects: | |
Online Access: | https://jcdr.net/articles/PDF/8373/19726_CE[Ra1]_F(GH)_PF1(ROAK)_PFA(GH)_PF2(PAG).pdf |
Summary: | Introduction: Dipyridamole inhibits adenosine reuptake and
increases cyclic Adenosine Monophosphate (cAMP) levels
in platelets, erythrocytes and endothelial cells, all of which
influence blood glucose. Acute hyperglycaemia reduces
endothelium-dependent vasodilation and suppresses coronary
microcirculation; which, in theory, can alter the outcome of a
radionuclide scan.
Aim: The present study was conducted with the aim to
investigate the changes in blood glucose level of patients
receiving dipyridamole for cardiac scan.
Materials and Methods: A total of 293 patients (85 men and
208 women, age: 60.59±10.43 years) were included in the study.
Fasting Blood Glucose (FBG) was measured before and 8 min
after dipyridamole (0.568 mg/kg) injection during myocardial
perfusion imaging. The data in different groups were analysed
by paired t-test.
Results: There was not a significant difference between first
(106.89 ± 19.21mg/dL) and second (107.98 ± 17.57 mg/dL)
FBG measurements (p= 0.293). However, when the patients
were grouped based on the quartiles of first measurement,
there was an increase in FBG following dipyridamole injection in
the first quartile (mean difference: 7.15±21.27 mg/dL, p<0.01);
in contrast, FBG levels showed a significant decrease after
dipyridamole administration in the 4th quartile (mean difference:
-9.53±18.20 mg/dL, p<0.001). The differences in 2nd and 3rd
quartiles were negligible. The patients were divided into normal,
ischemic and fixed lesions based on the outcome of scans,
then the possible correlation of dipyridamole-induced FBG
alteration and scan results were investigated. There were no
significant difference between the FBG values before and after
dipyridamole injection and the final outcome of scan.
Conclusion: The effects of dipyridamole on blood glucose
highly depend on the initial blood glucose level. |
---|---|
ISSN: | 2249-782X 0973-709X |